← Surfer · Coach Fuel hub · Animal fats · Sage depth

Coach — HydroEye

A bottle that edits membrane chemistry is not a mitochondrial gym. Flow first. Then the fork. Then, maybe, the softgel.

This essay is about HydroEye, an oral softgel that combines GLA, a scarce omega-6 fatty acid from black currant seed oil, with the omega-3s EPA and DHA and supporting nutrients.

The claim, said once: biology is energy flow. The surface of the eye is an open system that writes a three-layer tear film from two secretory engines. In this model, an oral GLA plus EPA and DHA formula does not raise mitochondrial voltage and does not grow the folded inner membranes called cristae. It edits which fatty acids sit in the membranes, and it steers a signaling fork toward a quieter prostaglandin, so less of the cell's energy is wasted on inflammatory leak and more of the gland's work becomes usable product. That is fuel plus membrane function. It is not conditioning of the energy chain.

Flow on a wet surface

Food electrons enter the cell at high energy. The mitochondrial energy chain lowers that state, pumps protons, and an enzyme called ATP synthase collects a toll in the form of ATP. When demand exceeds capacity, the cell compensates: less work, more sugar burning, more reactive oxygen, more pressure toward cell death. Chronic compensation, in this framework, is the metabolic spine of disease, a story of load versus capacity that runs from the mitochondrion to the tissue to the named syndromes clinics treat.

The eye makes that story unusually visible. Surface cells turn over constantly. The retinal ganglion cells of the optic nerve do not. Between them sit secretory engines: the tear-producing cells of the lacrimal gland and the oil-producing cells of the meibomian glands in the eyelids. They turn energy and fatty acids into a product that leaves the cell, tears and lid oil. If that product carries the wrong lipids, or if the gland spends its energy on inflammatory display instead of secretion, the film fails in public while the mitochondrion fails in private. People notice the public failure. Medicine often treats the public failure as if it were the whole engine.

Artificial tears replace volume for minutes. They do not change the fatty-acid makeup of the membranes that make the product, and they do not redirect the signaling fork that decides whether local chemistry spends energy on cleanup or on chronic irritation. Lubrication is merciful. It is not a repair.

In this model, what people call dry eye is often an unstable film plus salty, concentrated tears plus evaporative leak plus inflammatory drain. Concentration, evaporation, and inflammation are three different terms in the same budget, and the last one is wasted capacity. The bottle under discussion does not invent a new disease. It asks whether a membrane and signaling edit can shrink the waste so more of the gland's work becomes usable tears.

Number, area, and identity

A popular shorthand says that most of the body's membranes are mitochondrial. The real census is more careful. In a liver cell, mitochondrial membranes are a large but not total share of membrane area, the inner membrane larger than the outer because its folds multiply area. In a pancreatic cell built for secretion, other internal membranes dominate and the mitochondrial share falls. The near-eighty-percent figures usually describe the protein-to-lipid ratio inside the inner mitochondrial membrane, not a claim about every membrane in every tissue. Membrane function matters wherever mitochondria run. It is not a special property of the eye.

A cell's energy-chain capacity is roughly the product of four things: how many mitochondria it has, how much folded membrane each carries, how densely the machinery is packed, and how efficient the membrane is, which includes which fatty acids make up its walls. Dietary EPA and DHA can move that last term: in human muscle, weeks of fish oil have been shown to put those fatty acids into mitochondrial membranes and improve how the machinery handles its fuel, without changing the machinery itself or its maximal output. Losing cardiolipin collapses the folds. Adding GLA or EPA does not grow new ones. GLA is a weak building block for cardiolipin compared with linoleic acid or DHA, and human heart cardiolipin still prefers its linoleic-rich form.

So the line that matters is this: HydroEye is not a pill for building mitochondria and not a pill for growing folds. Saying otherwise inflates the claim. Number, area, and identity are three different dials. This formula, in the model, turns the identity dial and steers a signaling fork. It does not turn the other two.

The fork, in plain English

Linoleic acid, the common omega-6 fat, becomes GLA only through an enzyme step called delta-6 desaturase, which slows with age, insulin resistance, alcohol, and other modern insults. Supplemental GLA skips that bottleneck. GLA becomes DGLA, which can become a calming prostaglandin called PGE1, or, through a second enzyme, arachidonic acid and the more familiar inflammatory signals. EPA competes at that second enzyme, so DGLA is less likely to take the inflammatory road. DHA does membrane and inflammation-resolving work; it is not part of the PGE1 fork. One practical sentence: GLA plus EPA biases local signaling toward a quieter path, while EPA also does membrane work that DHA complements.

That chemistry helps explain why large trials of fish oil alone can fail dry-eye endpoints. They ask a different question from a GLA-plus-EPA formula. Small trials of the HydroEye formula, in narrow populations, have reported better symptom scores, reduced inflammatory markers on the eye's surface, and a smoother cornea compared with a sunflower-oil placebo. Other oral GLA work has shown tear PGE1 rising while people took the pills and falling when they stopped, with the surface relapsing. These are hypothesis-grade signals. They are not a license to say the bottle treats dry-eye disease, to borrow doses from other fields, or to fold it into AREDS2, macular degeneration marketing, or prescription eye care. HydroEye is a separate question from AREDS2.

The same fork runs in joints, skin, and nerves. Studies in rheumatoid arthritis have used grams of GLA and studies in neuropathy hundreds of milligrams; those are study amounts that show how other tissues respond, not a recipe. The eye looks special only because the tear gland uses PGE1 as a local signal you can measure in a drop of fluid, because dry eye is an open loop on a wet surface, and because a camera aimed at a few square centimeters of cornea is a better assay than a muscle biopsy. GLA is not eye-only biology wearing a brand name.

Where it sits

On the fuel side, this formula supplies scarce GLA and some EPA and DHA when wild fish is thin in the diet. Whole-body membrane work still belongs first to wild fish and to displacing the industrial linoleic overload described in the essay on toxins, with animal fats and proteins as the daily base. On the membrane side: fatty-acid identity yes, fold area no. On the energy chain: indirect only, through less inflammatory and concentration stress. Voltage, light, and load belong to other tools, such as methylene blue and strength training, each on its own hypothesis page. Sleep timing, mitochondrial building, and conditioning are not this tool's job.

It is also not a slogan that omega-6 is good now. Industrial linoleic excess and a deliberate GLA bypass are different sentences. One is the mismatch that frays membranes throughout the body. The other is a targeted skip around a slowed enzyme step, paired with EPA so the skip does not simply refill the inflammatory tank.

What it is not

EnSurf does not manufacture HydroEye; ScienceBased Health does. This essay is education, not a sales pitch, and gives no dosing or start-stop instructions. There is no claim that HydroEye increases cristae, mitochondrial number, or energy-chain volume, and no claim of glaucoma protection or rescue of retinal ganglion cells. It is not a substitute for lid mechanics, or for physician-directed surface therapy when an overactive immune response is the real drain. Combining HydroEye with prescription dry-eye drops is a question for your own physician.

Education first. Flow first. Then the fork. Then, if wild fish is thin in your diet and a physician who knows your case agrees the question is membrane chemistry rather than immune blockade on the surface, the softgel. The daily work underneath is still fuel, circadian timing, and strength. A membrane edit is an accessory, not the foundation. Discipline here is the refusal to let a branded softgel become the story of the eye, and the honesty to notice when a different specialty owns the lever that is actually stuck. For the condensed evidence, read the extended report on HydroEye.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 17, 2026.

Related: HydroEye on Surf Shop (sold through MDVite, EnSurf LLC’s store; not manufactured by EnSurf).

Related: Coach — Dry Eye and the Ocular Surface (Wipeouts · Ophthalmology).